Neuroscience
positron emission tomographic scan
100%
Antipsychotic
83%
Meta-Analysis
79%
Dopaminergic
69%
Fluorine-18
56%
In Vivo
55%
Positron Emission Tomography
55%
Receptor
53%
Glutamic Acid
48%
DOPA
47%
Striatum
46%
Clozapine
28%
Hippocampus
28%
Negative Syndrome
26%
Functional Magnetic Resonance Imaging
25%
Treatment-Resistant Schizophrenia
25%
Positive Syndrome
23%
Dopamine Release
19%
Nuclear Magnetic Resonance Spectroscopy
19%
Anterior Cingulate Cortex
19%
Midbrain
18%
Placebo
18%
Cannabis
17%
Gray Matter
16%
Working Memory
16%
Temporal Lobe
15%
Frontal Lobe
15%
Molecular Imaging
14%
Gamma-Aminobutyric Acid
14%
Blood Plasma
14%
Prefrontal Cortex
13%
Neuroscience
13%
Brain Imaging
12%
Ketamine
12%
Gray Matter Volume
12%
Bipolar Disorder
12%
Basal Ganglia
11%
Dopamine Transporter
11%
Behavior (Neuroscience)
10%
Microglia
10%
Functional Connectivity
10%
Amygdala
10%
Thalamus
9%
Tetrahydrocannabinol
9%
Raclopride
9%
Agonist
9%
Translocator Protein
9%
Amphetamine
9%
Synaptic Transmission
8%
Dopamine Receptor D2
8%
Medicine and Dentistry
Meta-Analysis
29%
Diseases
28%
Systematic Review
22%
Dopamine Metabolism
22%
Positron Emission Tomography
20%
Antipsychotic
19%
DOPA
14%
Pathophysiology
14%
Receptor
13%
Fluorine-18
10%
Polyethylene Terephthalate
10%
Dopamine Release
9%
Mental Health
8%
Striatum
8%
Effect Size
8%
Ketamine
8%
Side Effect
7%
Molecular Imaging
7%
Randomized Controlled Trial
7%
Negative Syndrome
7%
Volunteer
6%
Dopamine Transporter
6%
Psychopharmacology
6%
Placebo
6%
Drug Therapy
6%
Bipolar Disorder
5%
Vitamin D
5%
Triacylglycerol
5%
High Density Lipoprotein Cholesterol
5%
Glutamic Acid
5%
Pharmacology, Toxicology and Pharmaceutical Science
Antipsychotic
34%
Dopamine Receptor Stimulating Agent
24%
Clozapine
23%
Diseases
19%
Receptor
18%
Fluorine 18
14%
DOPA
12%
Polyethylene Terephthalate
10%
Treatment-Resistant Schizophrenia
9%
Glutamic Acid
9%
Placebo
8%
Ketamine
7%
Prolactin
7%
Normal Human
7%
Side Effect
6%
Psychopharmacology
6%
Cannabis
6%
Aripiprazole
6%
Carbon 11
6%
Insulin Resistance
5%
Tetrahydrocannabinol
5%
Vitamin D
5%
Negative Syndrome
5%
Pharmacotherapy
5%
Pathophysiology
5%